The Disposition of Prasugrel, a Novel Thienopyridine, in Humans-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The Disposition of Prasugrel, a Novel Thienopyridine, in Humans

Published:2007-04-02 Issue:7 Volume:35 Page:1096-1104
ISSN:0090-9556
Container-title:Drug Metabolism and Disposition
language:en
Short-container-title:Drug Metab Dispos

Author:

Farid Nagy A.,Smith Richard L.,Gillespie Todd A.,Rash T. James,Blair Patrick E.,Kurihara Atsushi,Goldberg Mark J.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmaceutical Science,Pharmacology

Reference13 articles.

1. Platelet inhibitory activity and pharmacokinetics of prasugrel (CS-747) a novel thienopyridine P2Y12 inhibitor: A single ascending dose study in healthy humans

2. Determination of the active and inactive metabolites of prasugrel in human plasma by liquid chromatography/tandem mass spectrometry

3. Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (Prasugrel, LY640315), a novel P2Y12 receptor inhibitor

4. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease

Cited by 198 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Contemporary Antiplatelet and Anticoagulant Therapies for Secondary Stroke Prevention: A Narrative Review of Current Literature and Guidelines;Current Neurology and Neuroscience Reports;2023-04-11

2. Dual Antiplatelet Therapy;Atrial Fibrillation - Diagnosis and Management in the 21st Century;2022-11-30

3. EFFECTIVENESS AND SAFETY COMPARISON OF P2Y12 RECEPTOR INHIBITORS IN PATIENTS WITH INVASIVE STRATEGY FOR ACUTE CORONARY SYNDROME;Tavricheskiy Mediko-Biologicheskiy Vestnik;2022-10-19

4. Clinical pharmacology of antiplatelet drugs;Expert Review of Clinical Pharmacology;2022-09-11

5. Influence of Genetic and Epigenetic Factors of P2Y12 Receptor on the Safety and Efficacy of Antiplatelet Drugs;Cardiovascular Drugs and Therapy;2022-08-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3